ArticleFrontiers in pharmacology2025

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost-utility analysis in China and the United States.

Qiuling Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.